To our knowledge, this study is the first to investigate the predictive and prognostic values of both LAG-3 and PD-L1 as serum biomarkers in HCC patients underwent TACE, and evaluate the dynamic changes of serum LAG-3 and PD-L1 levels in the context of TACE treatment. Here, CD274 is linked to hepatocellular carcinoma.